Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Epirubicin (4'-epi-adriamycin].

S Tsukagoshi1

  • 1Cancer Chemotherapy Center, Jap. Found. for Cancer Res., Tokyo.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1990
PubMed
Summary

Epirubicin, an anthracycline anticancer agent, demonstrates potent antitumor activity comparable or superior to doxorubicin. Clinical studies show efficacy across various cancers with reduced cardiotoxicity compared to doxorubicin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VALIDATION OF MONTE CARLO DOSE CALCULATION FOR PAEDIATRIC CT EXAMINATIONS USING TUBE CURRENT MODULATION BASED ON IN-PHANTOM DOSIMETRY.

Radiation protection dosimetry·2018
Same author

Buruli ulcer in a nine-month-old boy.

Annals of the Royal College of Surgeons of England·2012
Same author

[Comparison of management of advanced cancer in various organs].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].

Hinyokika kiyo. Acta urologica Japonica·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Epirubicin is a stereoisomer of doxorubicin, an anthracycline anticancer agent.
  • It shares a similar mechanism of action with doxorubicin, inhibiting DNA and RNA synthesis.

Purpose of the Study:

  • To evaluate the antitumor activity and pharmacodynamics of epirubicin.
  • To compare the cardiotoxicity of epirubicin with doxorubicin.

Main Methods:

  • Non-clinical experiments on transplantable murine tumors.
  • Clinical studies in Japan across various cancer types.
  • Comparative study of chronic cardiotoxicity using morphological, electrocardiographic, and histopathological indicators.

Main Results:

  • Epirubicin showed similar or superior antitumor effects compared to doxorubicin in preclinical models.
  • The drug demonstrated rapid tissue penetration and prolonged retention.
  • Epirubicin proved effective against a wide spectrum of solid tumors and hematopoietic malignancies.
  • Comparative studies indicated significantly reduced cardiotoxicity with epirubicin versus doxorubicin.

Conclusions:

  • Epirubicin is a novel antitumor agent with efficacy comparable or superior to doxorubicin.
  • Epirubicin offers a reduced toxicity profile, particularly regarding cardiotoxicity, compared to doxorubicin.

Related Experiment Videos